Note 13 - Notes Payable (Details Textual)
|
|
|
|
|
|
1 Months Ended |
8 Months Ended |
12 Months Ended |
|
|
|
|
Mar. 03, 2017
USD ($)
|
Jul. 01, 2016 |
Jun. 22, 2016
USD ($)
|
May 31, 2016
USD ($)
shares
|
Mar. 31, 2014
USD ($)
$ / shares
shares
|
Dec. 31, 2016
USD ($)
$ / shares
|
Jul. 31, 2016
USD ($)
shares
|
Jul. 31, 2015
USD ($)
|
May 31, 2015
USD ($)
$ / shares
|
Mar. 31, 2014
USD ($)
$ / shares
shares
|
Jun. 30, 2013
USD ($)
$ / shares
shares
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2016
USD ($)
$ / shares
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2013
USD ($)
|
Jun. 25, 2013
USD ($)
|
Feb. 28, 2017 |
Jul. 31, 2014
USD ($)
|
Jul. 31, 2012
USD ($)
|
| Repayments of Notes Payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 231,453
|
$ 30,333,333
|
$ 25,000,000
|
|
|
|
|
|
| Change in Fair Value of Financial Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,858,524
|
(614,782)
|
(1,342,389)
|
|
|
|
|
|
| Interest Payable, Current |
|
|
|
|
|
|
$ 5,756,519
|
|
|
|
|
|
$ 478
|
$ 5,756,519
|
478
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
[1] |
|
|
|
|
|
$ 0.33
|
|
|
|
|
|
|
$ 0.33
|
|
|
|
|
|
|
|
| Debt Instrument, Unamortized Discount |
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
2,033,506
|
$ 0
|
2,033,506
|
|
|
|
|
|
|
| Gain (Loss) on Extinguishment of Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,440,714)
|
(2,610,196)
|
|
|
|
|
|
| Equity Method Investment, Payment Upon Termination of Joint Venture |
|
|
|
|
|
|
|
|
|
|
|
|
|
110,000
|
|
|
|
|
|
|
|
| Interest Expense, Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
1,300,000
|
3,400,000
|
|
|
|
|
|
| Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
326,000
|
844,000
|
|
|
|
|
|
| Disposal Group, Including Discontinued Operation, Interest Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,856,404
|
5,603,820
|
326,337
|
|
|
|
|
|
| Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months |
|
|
|
|
|
|
52,000,000
|
|
|
|
|
|
|
52,000,000
|
|
|
|
|
|
|
|
| Long-term Debt, Maturities, Repayments of Principal in Year Two |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
| Long-term Debt, Maturities, Repayments of Principal in Year Three |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
| Long-term Debt, Maturities, Repayments of Principal in Year Four |
|
|
|
|
|
|
0
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
| Long-term Debt, Maturities, Repayments of Principal in Year Five |
|
|
|
|
|
|
9,500,000
|
|
|
|
|
|
|
9,500,000
|
|
|
|
|
|
|
|
| Long-term Debt, Maturities, Repayments of Principal after Year Five |
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
| R-NAV [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayments of Notes Payable |
|
|
|
|
|
|
|
$ 333,333
|
$ 333,333
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 666,666
|
|
| Equity Method Investment, Payment Upon Termination of Joint Venture |
|
|
|
|
$ 110,000
|
|
|
110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Method Investment, Forgiven Promissory Note, Amount |
|
|
|
|
$ 333,333
|
|
|
$ 333,333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-NAV [Member] | Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Method Investment, Shares Transferred Upon Termination of Joint Venture | shares |
|
|
|
|
1,500,000
|
|
|
1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-NAV [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Method Investment, Shares Transferred Upon Termination of Joint Venture | shares |
|
|
|
|
3,500,000
|
|
|
3,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series KK Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
|
|
|
|
|
$ 1.918
|
$ 1.918
|
|
|
|
$ 1.918
|
|
|
$ 1.918
|
|
|
|
|
|
|
|
| Series HH Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
|
|
|
|
|
|
2.49
|
|
|
|
|
|
|
2.49
|
|
|
|
|
|
|
|
| CRG Loan Agreement, Ohio Case [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Release of Cash Held in Escrow |
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CRG Loan Agreement, Texas Case [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Release of Cash Held in Escrow |
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
|
|
|
|
|
|
0.01
|
|
|
|
|
|
|
0.01
|
|
|
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
|
|
|
|
|
|
$ 3.04
|
|
|
|
|
|
|
$ 3.04
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | CRG Loan Agreement, Ohio Case [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Release of Cash Held in Escrow |
|
2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsequent Event [Member] | CRG Loan Agreement, Texas Case [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Release of Cash Held in Escrow |
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Federal Funds Rate [Member] | R-NAV [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.31%
|
|
| Platinum-Montaur Life Sciences LLC Litigation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Line of Credit Facility, Maximum Borrowing Capacity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000,000
|
| Line of Credit Facility, Current Borrowing Capacity |
|
|
|
|
|
|
|
|
|
|
|
$ 35,000,000
|
|
|
|
|
|
|
|
|
35,000,000
|
| Line of Credit Facility, Increase Additional Borrowings Terms Not Negotiated |
|
|
|
|
|
|
$ 15,000,000
|
|
|
|
|
|
|
$ 15,000,000
|
|
|
|
|
|
|
15,000,000
|
| Proceeds from Lines of Credit |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
4,500,000
|
0
|
$ 4,000,000
|
$ 8,000,000
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
10.00%
|
|
|
|
10.00%
|
10.00%
|
10.00%
|
|
|
|
|
|
|
|
|
|
| InterestRateInAdditionToAmendedAgreement |
|
|
|
|
|
|
|
|
|
|
|
0.125%
|
|
|
|
|
|
|
|
|
|
| Percentage of VWAP for Conversion Calculation |
|
|
|
|
|
|
|
|
|
|
|
90.00%
|
|
|
|
|
|
|
|
|
|
| Period of Preceding Date of Conversion Request |
|
|
|
|
|
|
|
|
|
|
|
10 days
|
|
|
|
|
|
|
|
|
|
| Minimum Revenue from Sales and Licensing for Mandatory Repayment Due |
|
|
|
|
|
|
|
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
| Repayments of Notes Payable |
|
|
|
|
|
|
|
|
|
|
|
$ 4,800,000
|
|
|
|
|
|
|
|
|
|
| Stock for Stock Conversion Number of Shares Converted | shares |
|
|
|
|
|
|
|
|
|
|
|
2,364.9
|
|
|
|
|
|
|
|
|
|
| Number of Common Shares Underlying Series B Preferred Stock | shares |
|
|
|
|
|
|
|
|
|
|
|
7,733,223
|
|
|
|
|
|
|
|
|
|
| Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock | shares |
|
|
|
|
|
|
|
|
|
|
|
3,270
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Convertible, Threshold Trading Days |
|
|
|
|
|
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Convertible, Stock Price Trigger | $ / shares |
|
|
|
|
|
|
|
|
|
$ 2.53
|
|
|
|
|
|
|
|
|
|
|
|
| Embedded Derivative, Fair Value of Embedded Derivative Liability |
|
|
|
|
|
|
153,000
|
|
|
|
|
|
|
153,000
|
|
|
|
|
|
|
|
| Change in Fair Value of Financial Instruments |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,900,000
|
(615,000)
|
(1,300,000)
|
|
|
|
|
|
| Convertible Debt, Fair Value Disclosures |
|
|
|
|
|
|
9,600,000
|
|
|
|
|
|
11,500,000
|
9,600,000
|
11,500,000
|
|
|
|
|
|
|
| Interest Expense, Debt, Excluding Amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000
|
761,000
|
|
|
|
|
|
|
| Line of Credit Facility, Decrease Forgiveness Interest Percentage |
|
|
6.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Notes Payable |
|
|
|
|
|
|
9,500,000
|
|
|
|
|
|
|
9,500,000
|
|
|
|
|
|
|
|
| Long-term Line of Credit |
|
|
|
|
|
|
7,700,000
|
|
|
|
|
|
|
7,700,000
|
|
|
|
|
|
|
|
| Interest Payable, Current |
|
|
|
|
|
|
1,800,000
|
|
|
|
|
|
|
1,800,000
|
|
|
|
|
|
|
|
| Line of Credit Facility, Remaining Borrowing Capacity |
|
|
|
|
|
|
27,300,000
|
|
|
|
|
|
|
27,300,000
|
|
|
|
|
|
|
|
| Platinum-Montaur Life Sciences LLC Litigation [Member] | Prime Rate [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Basis Spread on Variable Rate |
|
|
|
|
|
|
|
|
|
6.75%
|
6.75%
|
6.75%
|
|
|
|
|
|
|
|
|
|
| Platinum-Montaur Life Sciences LLC Litigation [Member] | Oxford Financing Rate [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Basis Spread on Variable Rate |
|
|
|
|
|
0.125%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Platinum-Montaur Life Sciences LLC Litigation [Member] | Interest Rate Pursuant to CRG Term Loan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Basis Spread on Variable Rate |
|
|
|
|
|
|
|
|
|
0.125%
|
|
|
|
|
|
|
|
|
|
|
|
| Platinum Loan Agreement [Member] | PPCO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Line of Credit Facility, Maximum Borrowing Capacity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000,000
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
8.125%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Debt, Fair Value Disclosures |
|
|
|
|
|
|
153,000
|
|
|
|
|
|
3,000,000
|
153,000
|
3,000,000
|
|
|
|
|
|
|
| Repayments of Debt |
|
7,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Debt |
|
1,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Platinum Loan Agreement [Member] | PPCO [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayments of Debt |
|
7,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible Debt |
|
1,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | Cardinal Health 414 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Letters of Credit Outstanding, Amount |
|
7,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Letters of Credit Outstanding, Amount |
|
12,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | Subsequent Event [Member] | Cardinal Health 414 [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Letters of Credit Outstanding, Amount |
|
7,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | Subsequent Event [Member] | CRG [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Letters of Credit Outstanding, Amount |
|
12,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit |
|
59,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
14.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Interest Expense, Debt, Excluding Amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
553,000
|
1,300,000
|
|
|
|
|
|
|
| Notes Payable |
|
|
|
|
|
|
51,700,000
|
|
|
|
|
|
51,300,000
|
51,700,000
|
51,300,000
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
$ 50,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions |
|
|
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of Per Annum Interest Paying in Cash |
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of Per Annum Interest as Compounded Interest |
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Number of Quarterly Payments |
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument Payment Terms Payment Period |
|
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Unamortized Discount (Premium), Net |
|
|
|
|
|
|
|
|
|
$ 2,200,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument End of Term Fee, Amount |
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Fee Amount |
|
|
|
|
|
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Covenant Compliance, Income (Loss) Earnings Before Interest, Taxes, Depreciation, and Amortization, Minimum |
|
|
|
|
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Covenant Compliance Sales Revenue Minimum Next Twelve Months |
|
|
|
|
|
|
22,500,000
|
|
|
|
|
|
|
22,500,000
|
|
|
|
|
|
|
|
| DebtInstrumentCovenantComplianceTargetRevenueMinimum |
|
|
|
|
|
|
|
|
|
$ 45,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Covenant Compliance Cure Right Ratio |
|
|
|
|
|
|
|
|
|
2.5
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Covenant Compliance Liquidity Minimum |
|
|
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate in the Event of Default |
|
|
|
|
|
|
|
|
|
18.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Primary Bank Account Cash Taken Possession Of By Creditor |
|
|
|
$ 4,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Prepayment Premium and Backend Facility Fee on Claims of Default |
|
|
|
3,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Principal Balance of Debt on Claims of Default |
|
|
|
$ 189,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit |
|
59,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Agreed-upon Final Payoff Amount |
|
66,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.00%
|
|
|
| Repayments of Debt |
|
59,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit |
|
59,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Agreed-upon Final Payoff Amount |
|
47,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Agreed-upon Final Payoff Amount |
|
$ 66,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term Loan Agreement [Member] | CRG [Member] | Accrued Liabilities and Other [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest Payable, Current |
|
|
|
|
|
|
$ 5,800,000
|
|
|
|
|
|
0
|
$ 5,800,000
|
0
|
|
|
|
|
|
|
| Oxford Finance, LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
8.50%
|
|
|
|
|
8.50%
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
$ 30,000,000
|
|
|
|
|
$ 30,000,000
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Unamortized Discount (Premium), Net |
|
|
|
|
|
3,000,000
|
|
|
|
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument End of Term Fee, Amount |
|
|
|
|
|
|
|
|
|
|
2,400,000
|
|
2,400,000
|
|
|
|
|
|
|
|
|
| Repayments of Long-term Debt |
|
|
|
|
|
|
|
|
|
$ 31,700,000
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Early Redemption Fee Amount |
|
|
|
|
|
|
|
|
|
$ 289,000
|
|
|
|
|
|
|
|
|
|
|
|
| Long-term Debt, Gross |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
$ 0
|
|
|
|
|
|
|
| Oxford Finance, LLC [Member] | Series KK Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Unamortized Discount (Premium), Net |
|
|
|
|
|
$ 120,000
|
|
|
|
|
$ 120,000
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares |
|
|
|
|
|
391,032
|
|
|
|
|
391,032
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
|
|
|
|
|
$ 1.918
|
|
|
|
|
$ 1.918
|
|
|
|
|
|
|
|
|
|
|
| GECC/MidCap Financial SBIC LP [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
|
|
|
|
|
9.83%
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
|
|
|
|
|
$ 25,000,000
|
|
|
|
|
|
|
|
|
|
| Debt Instrument End of Term Fee, Amount |
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
| Repayments of Long-term Debt |
|
|
|
|
|
|
|
|
|
|
26,700,000
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Early Redemption Fee Amount |
|
|
|
|
|
$ 500,000
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
| Long-term Debt, Gross |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
| Number of Monthly Installment Payments on Notes Payable |
|
|
|
|
|
|
|
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
| Percentage of Original Principal Amount of Loan to Be Paid as Fee |
|
|
|
|
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Unamortized Discount |
|
|
|
|
|
|
|
|
|
|
|
$ 881,000
|
|
|
|
|
|
|
|
|
|
| Gain (Loss) on Extinguishment of Debt |
|
|
|
|
|
|
|
|
|
|
$ 2,600,000
|
|
|
|
|
|
|
|
|
|
|
| GECC/MidCap Financial SBIC LP [Member] | Series HH Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares |
|
|
|
|
|
|
|
|
|
|
|
301,205
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
$ 2.49
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Unamortized Discount |
|
|
|
|
|
|
|
|
|
|
|
$ 1,900,000
|
|
|
|
|
|
|
|
|
|
| Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
8.99%
|
|
|
|
|
|
|
8.99%
|
|
|
|
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
$ 348,000
|
|
|
|
|
|
|
$ 348,000
|
|
|
|
|
|
|
|
| Debt Instrument, Term |
|
|
|
|
|
|
240 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Periodic Payment |
|
|
|
|
|
|
$ 45,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|